Concepts (201)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hyperlipoproteinemia Type II | 11 | 2023 | 395 | 2.090 |
Why?
|
| Blood Component Removal | 7 | 2020 | 132 | 1.650 |
Why?
|
| Lipoproteins, LDL | 3 | 2013 | 642 | 0.710 |
Why?
|
| Atherosclerosis | 13 | 2023 | 3400 | 0.670 |
Why?
|
| Carotid Artery Diseases | 7 | 2021 | 877 | 0.580 |
Why?
|
| Human Growth Hormone | 9 | 2013 | 642 | 0.580 |
Why?
|
| Cholesterol, LDL | 10 | 2023 | 2378 | 0.490 |
Why?
|
| Colestipol | 1 | 2014 | 11 | 0.490 |
Why?
|
| Anticholesteremic Agents | 3 | 2023 | 967 | 0.450 |
Why?
|
| Niacin | 1 | 2014 | 118 | 0.440 |
Why?
|
| Physicians, Primary Care | 1 | 2020 | 618 | 0.430 |
Why?
|
| Lipoproteins | 4 | 2015 | 879 | 0.410 |
Why?
|
| Maximum Tolerated Dose | 1 | 2013 | 883 | 0.370 |
Why?
|
| Hyperlipoproteinemia Type I | 2 | 2019 | 11 | 0.320 |
Why?
|
| Carotid Arteries | 8 | 2022 | 941 | 0.320 |
Why?
|
| Tunica Media | 4 | 2011 | 110 | 0.290 |
Why?
|
| HIV Infections | 14 | 2022 | 17342 | 0.270 |
Why?
|
| Oligonucleotides | 2 | 2019 | 566 | 0.260 |
Why?
|
| Tunica Intima | 4 | 2011 | 458 | 0.250 |
Why?
|
| Triglycerides | 6 | 2020 | 2459 | 0.230 |
Why?
|
| Uganda | 8 | 2022 | 1332 | 0.230 |
Why?
|
| Abdominal Fat | 3 | 2013 | 221 | 0.200 |
Why?
|
| Lung Diseases, Obstructive | 1 | 2022 | 308 | 0.180 |
Why?
|
| HIV Seronegativity | 1 | 2021 | 211 | 0.180 |
Why?
|
| Heterozygote | 3 | 2019 | 2780 | 0.180 |
Why?
|
| Obesity, Abdominal | 2 | 2013 | 373 | 0.170 |
Why?
|
| Cardiovascular Diseases | 14 | 2023 | 15498 | 0.170 |
Why?
|
| Growth Hormone-Releasing Hormone | 2 | 2012 | 128 | 0.160 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 2 | 2018 | 283 | 0.160 |
Why?
|
| Homozygote | 2 | 2023 | 1776 | 0.160 |
Why?
|
| Anti-HIV Agents | 4 | 2021 | 4524 | 0.160 |
Why?
|
| Urban Health | 1 | 2021 | 532 | 0.160 |
Why?
|
| Body Composition | 8 | 2013 | 2426 | 0.150 |
Why?
|
| Acromegaly | 2 | 2012 | 310 | 0.150 |
Why?
|
| Apolipoprotein C-III | 1 | 2019 | 210 | 0.150 |
Why?
|
| Decision Support Techniques | 2 | 2018 | 1999 | 0.140 |
Why?
|
| HIV Seropositivity | 1 | 2021 | 959 | 0.130 |
Why?
|
| Plaque, Atherosclerotic | 2 | 2021 | 1533 | 0.130 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 3 | 2017 | 3245 | 0.130 |
Why?
|
| Fasting | 1 | 2020 | 1603 | 0.110 |
Why?
|
| Foundations | 1 | 2013 | 95 | 0.110 |
Why?
|
| Endothelium, Vascular | 2 | 2018 | 4433 | 0.100 |
Why?
|
| Antigens, CD | 3 | 2018 | 3998 | 0.100 |
Why?
|
| Registries | 6 | 2023 | 8209 | 0.100 |
Why?
|
| Anti-Retroviral Agents | 2 | 2016 | 1783 | 0.100 |
Why?
|
| Risk Factors | 22 | 2022 | 74128 | 0.100 |
Why?
|
| Rural Population | 2 | 2020 | 2277 | 0.100 |
Why?
|
| Cell Adhesion Molecules | 1 | 2018 | 1602 | 0.100 |
Why?
|
| Middle Aged | 35 | 2022 | 220603 | 0.100 |
Why?
|
| Inflammation Mediators | 2 | 2018 | 1884 | 0.100 |
Why?
|
| Thrombocytopenia | 1 | 2019 | 1182 | 0.090 |
Why?
|
| Receptors, Cell Surface | 2 | 2018 | 2802 | 0.090 |
Why?
|
| HIV | 1 | 2018 | 1580 | 0.090 |
Why?
|
| Insulin-Like Growth Factor I | 3 | 2013 | 1932 | 0.090 |
Why?
|
| Coronary Disease | 2 | 2016 | 5911 | 0.090 |
Why?
|
| Phosphocreatine | 1 | 2010 | 261 | 0.090 |
Why?
|
| Arteries | 1 | 2014 | 1120 | 0.080 |
Why?
|
| Humans | 45 | 2023 | 760740 | 0.080 |
Why?
|
| Azetidines | 1 | 2010 | 142 | 0.080 |
Why?
|
| Adult | 31 | 2022 | 220995 | 0.080 |
Why?
|
| Cholesterol, HDL | 4 | 2020 | 1810 | 0.080 |
Why?
|
| Treatment Outcome | 10 | 2020 | 64572 | 0.080 |
Why?
|
| Carotid Artery, Common | 2 | 2006 | 175 | 0.080 |
Why?
|
| Arginine | 2 | 2010 | 933 | 0.080 |
Why?
|
| Cross-Sectional Studies | 9 | 2022 | 26065 | 0.080 |
Why?
|
| Fingers | 1 | 2011 | 506 | 0.070 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 1 | 2011 | 558 | 0.070 |
Why?
|
| Receptors, LDL | 1 | 2010 | 488 | 0.070 |
Why?
|
| Obesity | 5 | 2012 | 12934 | 0.070 |
Why?
|
| HIV-Associated Lipodystrophy Syndrome | 1 | 2008 | 138 | 0.070 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2016 | 1894 | 0.070 |
Why?
|
| Male | 31 | 2022 | 360402 | 0.070 |
Why?
|
| Female | 34 | 2022 | 392203 | 0.070 |
Why?
|
| Growth Hormone | 1 | 2008 | 569 | 0.070 |
Why?
|
| Health Status Disparities | 1 | 2017 | 1846 | 0.060 |
Why?
|
| Radiography | 2 | 2014 | 6961 | 0.060 |
Why?
|
| Case-Control Studies | 6 | 2021 | 22153 | 0.060 |
Why?
|
| Botswana | 2 | 2018 | 1049 | 0.060 |
Why?
|
| RNA, Messenger | 1 | 2019 | 12759 | 0.060 |
Why?
|
| Metformin | 1 | 2012 | 906 | 0.060 |
Why?
|
| Hormone Replacement Therapy | 1 | 2010 | 751 | 0.060 |
Why?
|
| Adiponectin | 2 | 2008 | 1107 | 0.060 |
Why?
|
| Double-Blind Method | 6 | 2019 | 12333 | 0.050 |
Why?
|
| Lung | 1 | 2022 | 9999 | 0.050 |
Why?
|
| Risk Assessment | 6 | 2021 | 23974 | 0.050 |
Why?
|
| Protease Inhibitors | 1 | 2006 | 753 | 0.050 |
Why?
|
| Coronary Artery Disease | 2 | 2020 | 6403 | 0.050 |
Why?
|
| Ultrasonography | 5 | 2020 | 5965 | 0.050 |
Why?
|
| Pre-Eclampsia | 1 | 2011 | 1230 | 0.050 |
Why?
|
| Adiposity | 1 | 2012 | 1879 | 0.050 |
Why?
|
| Smoking | 2 | 2022 | 9054 | 0.050 |
Why?
|
| Life Style | 1 | 2012 | 3907 | 0.040 |
Why?
|
| Intercellular Adhesion Molecule-1 | 2 | 2018 | 1128 | 0.040 |
Why?
|
| C-Reactive Protein | 5 | 2013 | 3820 | 0.040 |
Why?
|
| Testosterone | 1 | 2010 | 2472 | 0.040 |
Why?
|
| United States | 6 | 2023 | 72292 | 0.040 |
Why?
|
| Hypoglycemic Agents | 1 | 2012 | 3085 | 0.040 |
Why?
|
| Clinical Trials as Topic | 1 | 2014 | 7995 | 0.040 |
Why?
|
| Spirometry | 1 | 2022 | 928 | 0.040 |
Why?
|
| Lipids | 4 | 2012 | 3332 | 0.040 |
Why?
|
| Patient Selection | 1 | 2010 | 4237 | 0.040 |
Why?
|
| Longitudinal Studies | 3 | 2021 | 14599 | 0.040 |
Why?
|
| Injections, Subcutaneous | 1 | 2019 | 671 | 0.040 |
Why?
|
| Mass Screening | 1 | 2013 | 5425 | 0.040 |
Why?
|
| Placebos | 2 | 2012 | 1667 | 0.040 |
Why?
|
| Regression Analysis | 4 | 2013 | 6339 | 0.040 |
Why?
|
| Chi-Square Distribution | 2 | 2016 | 3410 | 0.040 |
Why?
|
| Gene Expression Regulation | 1 | 2015 | 11874 | 0.040 |
Why?
|
| Aged | 11 | 2022 | 169092 | 0.040 |
Why?
|
| Young Adult | 8 | 2019 | 59191 | 0.030 |
Why?
|
| Down-Regulation | 2 | 2016 | 2916 | 0.030 |
Why?
|
| Respiratory Function Tests | 1 | 2022 | 1683 | 0.030 |
Why?
|
| Prevalence | 3 | 2021 | 15702 | 0.030 |
Why?
|
| Pilot Projects | 3 | 2017 | 8619 | 0.030 |
Why?
|
| Overweight | 1 | 2008 | 2417 | 0.030 |
Why?
|
| Forced Expiratory Volume | 1 | 2022 | 1814 | 0.030 |
Why?
|
| Platelet Count | 1 | 2019 | 780 | 0.030 |
Why?
|
| E-Selectin | 1 | 2018 | 577 | 0.030 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 1 | 2018 | 691 | 0.030 |
Why?
|
| Analysis of Variance | 2 | 2019 | 6223 | 0.030 |
Why?
|
| Time Factors | 4 | 2021 | 39908 | 0.030 |
Why?
|
| Cohort Studies | 4 | 2022 | 41464 | 0.030 |
Why?
|
| Cardiovascular System | 2 | 2013 | 834 | 0.030 |
Why?
|
| Biostatistics | 1 | 2016 | 163 | 0.030 |
Why?
|
| Inflammation | 1 | 2014 | 10759 | 0.030 |
Why?
|
| Odds Ratio | 2 | 2017 | 9644 | 0.030 |
Why?
|
| Prospective Studies | 4 | 2021 | 54364 | 0.030 |
Why?
|
| Lovastatin | 1 | 1994 | 115 | 0.030 |
Why?
|
| Africa South of the Sahara | 1 | 2017 | 745 | 0.030 |
Why?
|
| Aging | 1 | 2013 | 8700 | 0.030 |
Why?
|
| Hypercholesterolemia | 1 | 2020 | 1141 | 0.030 |
Why?
|
| Predictive Value of Tests | 2 | 2021 | 15250 | 0.030 |
Why?
|
| Health Records, Personal | 1 | 2013 | 127 | 0.030 |
Why?
|
| Multicenter Studies as Topic | 1 | 2017 | 1700 | 0.030 |
Why?
|
| American Heart Association | 1 | 2017 | 1039 | 0.020 |
Why?
|
| Cholesterol | 2 | 2006 | 2902 | 0.020 |
Why?
|
| Cellulose | 1 | 2011 | 117 | 0.020 |
Why?
|
| Sex Factors | 2 | 2017 | 10549 | 0.020 |
Why?
|
| Early Diagnosis | 1 | 2016 | 1185 | 0.020 |
Why?
|
| Adrenal Insufficiency | 1 | 2012 | 194 | 0.020 |
Why?
|
| Dextran Sulfate | 1 | 2011 | 258 | 0.020 |
Why?
|
| Pulsatile Flow | 1 | 2011 | 320 | 0.020 |
Why?
|
| Hyperemia | 1 | 2011 | 221 | 0.020 |
Why?
|
| Mitochondria, Muscle | 1 | 2010 | 172 | 0.020 |
Why?
|
| Solubility | 1 | 2011 | 1089 | 0.020 |
Why?
|
| Viral Load | 1 | 2018 | 3325 | 0.020 |
Why?
|
| Phenotype | 2 | 2017 | 16572 | 0.020 |
Why?
|
| Manometry | 1 | 2011 | 453 | 0.020 |
Why?
|
| Multivariate Analysis | 2 | 2016 | 12043 | 0.020 |
Why?
|
| Cardiology | 1 | 2019 | 1656 | 0.020 |
Why?
|
| Interleukin-6 | 1 | 2018 | 3205 | 0.020 |
Why?
|
| Monocytes | 1 | 2017 | 2565 | 0.020 |
Why?
|
| Asymptomatic Diseases | 1 | 2011 | 587 | 0.020 |
Why?
|
| Intra-Abdominal Fat | 1 | 2012 | 612 | 0.020 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type II | 1 | 2008 | 344 | 0.020 |
Why?
|
| Body Mass Index | 3 | 2009 | 12942 | 0.020 |
Why?
|
| Blood Glucose | 2 | 2012 | 6390 | 0.020 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2014 | 2008 | 0.020 |
Why?
|
| Guideline Adherence | 1 | 2016 | 2218 | 0.020 |
Why?
|
| Boston | 2 | 2011 | 9313 | 0.020 |
Why?
|
| Anthropometry | 1 | 2009 | 1338 | 0.020 |
Why?
|
| Protein Structure, Tertiary | 1 | 2011 | 3793 | 0.010 |
Why?
|
| Disease Progression | 1 | 2021 | 13495 | 0.010 |
Why?
|
| Adolescent | 4 | 2012 | 88247 | 0.010 |
Why?
|
| Exercise Test | 1 | 2010 | 2127 | 0.010 |
Why?
|
| Coronary Angiography | 1 | 1994 | 4470 | 0.010 |
Why?
|
| Body Size | 1 | 2005 | 463 | 0.010 |
Why?
|
| Hormones | 1 | 2006 | 869 | 0.010 |
Why?
|
| Healthcare Disparities | 1 | 2017 | 3351 | 0.010 |
Why?
|
| Internet | 1 | 2013 | 3094 | 0.010 |
Why?
|
| Comorbidity | 1 | 2016 | 10507 | 0.010 |
Why?
|
| Logistic Models | 1 | 2016 | 13248 | 0.010 |
Why?
|
| Databases, Factual | 1 | 2016 | 7963 | 0.010 |
Why?
|
| Cytokines | 1 | 2015 | 7373 | 0.010 |
Why?
|
| Retrospective Studies | 2 | 2020 | 80583 | 0.010 |
Why?
|
| Mitochondria | 1 | 2013 | 3619 | 0.010 |
Why?
|
| Massachusetts | 1 | 2013 | 8835 | 0.010 |
Why?
|
| Sex Characteristics | 1 | 2009 | 2637 | 0.010 |
Why?
|
| Absorptiometry, Photon | 1 | 2005 | 1738 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2006 | 3798 | 0.010 |
Why?
|
| Practice Guidelines as Topic | 1 | 2016 | 7390 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 2008 | 6520 | 0.010 |
Why?
|
| Risk | 1 | 2010 | 9603 | 0.010 |
Why?
|
| Physicians | 1 | 2016 | 4583 | 0.010 |
Why?
|
| Positron-Emission Tomography | 1 | 2014 | 6483 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2019 | 39062 | 0.010 |
Why?
|
| Reference Values | 1 | 2005 | 4919 | 0.010 |
Why?
|
| Diabetes Mellitus | 1 | 2016 | 5838 | 0.010 |
Why?
|
| Quality of Life | 2 | 2010 | 13359 | 0.010 |
Why?
|
| Electronic Health Records | 1 | 2013 | 4810 | 0.010 |
Why?
|
| Hypertension | 1 | 2016 | 8532 | 0.010 |
Why?
|
| Muscle, Skeletal | 1 | 2010 | 4947 | 0.010 |
Why?
|
| Hemodynamics | 1 | 2006 | 4160 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2016 | 17878 | 0.010 |
Why?
|
| Insulin Resistance | 1 | 2008 | 3954 | 0.010 |
Why?
|
| Adipose Tissue | 1 | 2006 | 3310 | 0.010 |
Why?
|
| Insulin | 1 | 2008 | 6593 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2018 | 58919 | 0.010 |
Why?
|
| Blood Pressure | 1 | 2008 | 8473 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2014 | 20556 | 0.010 |
Why?
|
| Pregnancy | 1 | 2011 | 29869 | 0.010 |
Why?
|
Concepts
(201)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(38)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_
Physical Neighbors
People whose addresses are nearby this person.
_